[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)]

    Insights

    This updated consensus guides clinical practice for chronic graft-versus-host disease (cGVHD), a severe complication after stem cell transplants. It incorporates new therapies and research for better diagnosis and management.

    Area of Science:

    • Hematology
    • Immunology
    • Oncology

    Context:

    • Chronic graft-versus-host disease (cGVHD) is a significant complication of allogeneic hematopoietic stem cell transplantation (HSCT).
    • cGVHD severely impacts patient survival and quality of life post-HSCT.
    • Existing clinical guidelines require updates to reflect recent advancements.

    Purpose:

    • To revise and update the Chinese consensus on the diagnosis and management of cGVHD.
    • To provide current, evidence-based guidance for clinicians treating cGVHD.
    • To integrate novel therapeutic strategies and recent research findings into clinical practice.

    Summary:

    • The consensus incorporates the latest developments in cGVHD research and evidence-based medicine.
    • Novel therapies, including targeted drugs, and advancements in clinical research have driven progress.
    • This revised guideline aims to optimize the diagnosis, prevention, and treatment of cGVHD.

    Impact:

    • Improved clinical management strategies for cGVHD patients.
    • Enhanced patient outcomes and quality of life following HSCT.
    • Standardized and up-to-date guidance for healthcare professionals managing cGVHD.